Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis

British Journal of Haematology

Volumn 153, Issue 5, 2011, Pages 589-598

  Takeda, Yusuke ^a   Nakaseko, Chiaki ^a   Tanaka, Hiroaki ^a   Takeuchi, Masahiro ^a   Yui, Makiko ^a   Saraya, Atsunori ^a,c   Miyagi, Satoru ^a,c   Wang, Changshan ^a,c   Tanaka, Satomi ^a   Ohwada, Chikako ^a   Sakaida, Emiko ^a   Yamaguchi, Naoto ^a   Yokote, Koutaro ^a   Hennighausen, Lothar ^b   Iwama, Atsushi ^a,c  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

ETV6 LYN; Myelofibrosis; Myeloproliferative neoplasm; STAT5

Indexed keywords

ETV6 LYN PROTEIN; HYBRID PROTEIN; JANUS KINASE 2; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RISK FACTOR;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED C57BL; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PRIMARY MYELOFIBROSIS; PROTO-ONCOGENE PROTEINS C-ETS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT5 TRANSCRIPTION FACTOR;

EID: 79955730965     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08663.x     Document Type: Article

References (38)

1. Abe, A., Emi, N., Kanie, T., Imagama, S., Kuno, Y., Takahashi, M., Saito, H. & Naoe, T. (2004) Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. Biochemical Biophysical Research Communications, 320, 920-926.
2. Benekli, M., Baer, M.R., Baumann, H. & Wetzler, M. (2003) Signal transducer and activator of transcription proteins in leukemias. Blood, 101, 2940-2954.
3. Bohlander, S.K. (2005) ETV6: a versatile player in leukemogenesis. Seminars in Cancer Biology, 15, 162-174.
4. Cain, J.A., Xiang, Z., O'Neal, J., Kreisel, F., Colson, A., Luo, H., Hennighausen, L. & Tomasson, M.H. (2007) Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood, 109, 3906-3914.
5. Chin, H., Arai, A., Wakao, H., Kamiyama, R., Miyasaka, N. & Miura, O. (1998) Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood, 91, 3734-3745.
6. Cui, Y., Riedlinger, G., Miyoshi, K., Tang, W., Li, C., Deng, C.X., Robinson, G.W. & Hennighausen, L. (2004) Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Molecular and Cellular Biology, 24, 8037-8047.
7. Dai, X., Chen, Y., Di, L., Podd, A., Li, G., Bunting, K.D., Hennighausen, L., Wen, R. & Wang, D. (2007) Stat5 is essential for early B cell development but not for B cell maturation and function. Journal of Immunology, 179, 1068-1079.
8. Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R. & Talpaz, M. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, 690-698.
9. Dos Santos, C., Demur, C., Bardet, V., Prade-Houdellier, N., Payrastre, B. & Recher, C. (2008) A critical role for Lyn in acute myeloid leukemia. Blood, 111, 2269-2279.
10. Hennighausen, L. & Robinson, G.W. (2008) Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes and Development, 22, 711-721.
11. Heuser, M., Sly, L.M., Argiropoulos, B., Kuchenbauer, F., Lai, C., Weng, A., Leung, M., Lin, G., Brookes, C., Fung, S., Valk, P.J., Delwel, R., Löwenberg, B., Krystal, G. & Humphries, R.K. (2009) Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood, 114, 3983-3993.
12. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M. & Fabbro, D. (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics, 36, 453-461.
13. Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., van Lohuizen, M. & Nakauchi, H. (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity, 21, 843-851.
14. James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
15. Kasahara, K., Nakayama, Y., Ikeda, K., Fukushima, Y., Matsuda, D., Horimoto, S. & Yamaguchi, N. (2004) Trafficking of Lyn through the Golgi caveolin involves the charged residues on αE and αI helices in the kinase domain. Journal of Cell Biology, 165, 641-652.
16. Kato, Y., Iwama, A., Tadokoro, Y., Shimoda, K., Minoguchi, M., Akira, S., Tanaka, M., Miyajima, A., Kitamura, T. & Nakauchi, H. (2005) Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. Journal of Experimental Medicine, 202, 169-179.
17. Kitamura, T., Koshino, Y., Shibata, F., Okia, T., Nakajima, H., Nosaka, T. & Kumagai, H. (2003) Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Experimental Hematology, 31, 1007-1014.
18. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779-1790.
19. Lacout, C., Pisani, D.F., Tulliez, M., Gachelin, F.M., Vainchenker, W. & Villeval, J.L. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, 108, 1652-1660.
20. Levine, R.L. & Gilliland, D.G. (2008) Myeloproliferative disorders. Blood, 112, 2190-2198.
21. Li, G., Wang, Z., Zhang, Y., Kang, Z., Haviernikova, E., Cui, Y., Hennighausen, L., Moriggl, R., Wang, D., Tse, W. & Bunting, K.D. (2007) STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Experimental Hematology, 35, 1684-1694.
22. Martyré, M.C., Romquin, N., Le Bousse-Kerdiles, M.C., Chevillard, S., Benyahia, B., Dupriez, B., Demory, J.L. & Bauters, F. (1994) Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. British Journal of Haematology, 88, 9-16.
23. Palacios, R. & Steinmetz, M. (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell, 41, 727-734.
24. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. & Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-3476.
25. Pear, W.S., Miller, J.P., Xu, L., Pui, J.C., Soffer, B., Quackenbush, R.C., Pendergast, A.M., Bronson, R., Aster, J.C., Scott, M.L. & Baltimore, D. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood, 92, 3780-3792.
26. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., DeAngelo, D.J., Clark, J.J., Lee, S.J., Golub, T.R., Wadleigh, M., Gilliland, D.G. & Levine, R.L. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3, e270.
27. Ptasznik, A., Nakata, Y., Kalota, A., Emerson, S.G. & Gewirtz, A.M. (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nature Medicine, 10, 1187-1189.
28. Schreiner, S.J., Schiavone, A.P. & Smithgall, T.E. (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. Journal of Biological Chemistry, 277, 45680-45687.
29. Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C., Williams, I.R., Lee, C.K., Gerthner, R., Kitamura, T., Frantsve, J., Anastasiadou, E., Loh, M.L., Levy, D.E., Ihle, J.N. & Gilliland, D.G. (2000) Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Molecular Cell, 6, 693-704.
30. Silva, C. (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigensis. Oncogene, 23, 8017-8123.
31. Takeuchi, M., Nakaseko, C., Miyagi, S., Takeda, Y., Ozawa, S., Ohwada, C., Cho, R., Nishimura, M., Saito, Y. & Iwama, A. (2008) Clonal expansion of non-leukemic cells expressing two novel MLL-ELL variants differing in transforming activity. Leukemia, 22, 861-864.
32. Tanaka, H., Takeuchi, M., Takeda, Y., Sakai, S., Abe, D., Ohwada, C., Sakaida, E., Shimizu, N., Saito, Y., Miyagi, S., Iwama, A. & Nakaseko, C. (2010) Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia, 24, 197-200.
33. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
34. Tilbrook, P.A., Ingley, E., Williams, J.H., Hibbs, M.L. & Klinken, S.P. (1997) Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO Journal, 16, 1610-1619.
35. Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H. & Gilliland, D.G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 107, 4274-4281.
36. Xu, Y., Harder, K.W., Huntington, N.D., Hibbs, M.L. & Tarlinton, D.M. (2005) Lyn tyrosine kinase: accentuating the positive and the negative. Immunity, 22, 9-18.
37. Yao, Z., Cui, Y., Watford, W.T., Bream, J.H., Yamaoka, K., Hissong, B.D., Li, D., Durum, S.K., Jiang, Q., Bhandoola, A., Hennighausen, L. & O'Shea, J.J. (2006) Stat5a/b are essential for normal lymphoid development and differentiation. Proceedings of the National academy of Sciences of the United States of America, 103, 1000-1005.
38. Zaleskas, V.M., Krause, D.S., Lazarides, K., Patel, N., Hu, Y., Li, S. & Van Etten, R.A. (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE, 1, e18.